Europe
Early-Stage Business Accelerator to Empower Local MedTech Innovation and Enhance Medtronic China’s Industry Leadership
Immuno-oncology has become a key lynchpin in the pipelines of many pharmaceutical companies. The global cancer immunotherapy market is expected to more than double over the next eight years to $126.9 billion by 2026.
GATTO Study Extension to Evaluate Gatipotuzumab and Tomuzotuximab or marketed anti-EGFR Monoclonal Antibody Drugs in refractory metastatic solid tumors
Karolinska Development’s portfolio company Aprea Therapeutics announces that Dr. Eyal C. Attar has been appointed to a position as Senior Vice President and Chief Medical Officer (CMO).
BioArctic AB announces that its partner Eisai will give poster presentations related to BAN2401 in early Alzheimer’s disease at the 14th International Conference on Alzheimer’s & Parkinson’s Diseases on March 27 in Lisbon, Portugal.
The Principals MENA (TPM), a fast-growing brand marketing company in the Middle East and North Africa (MENA), recently launched its latest range of best-in-class health, skin and hair care products from a network of leading international partners, at a special launching event held at V Hotel, The Palm.
Foundations increasingly play a large role in funding basic science both domestically and internationally. Recently, The Michael J. Fox Foundation for Parkinson’s Research (MJFF) granted Dublin and Cambridge, UK-based Inflazome more than $1 million.
Both Bayer and J&J claim the lawsuits are without merit but believe that the $775 million settlement will allow the companies to move on from costly litigation.
Brisbane, Calif.-based Aimmune Therapeutics announced that its Phase III European clinical trial of AR101 for treatment of peanut allergy met its primary efficacy endpoint.
Immunicum AB announced that members of the management team will attend and present at upcoming conferences in March and April.
PRESS RELEASES